Under the first-tier compliance regulations, which statement best describes 21 CFR Part 211 (subparts A-K)?

Under the first-tier compliance regulations, which statement best describes 21 CFR Part 211 (subparts A-K)?

• A. Pharmacovigilance requirements
• B. Adverse event reporting standards
• C. Complete Good Laboratory Practices
• D. Minimum current Good Manufacturing Practices for finished pharmaceuticals

Answer: (D)

The statement tested here hinges on recognizing what 21 CFR Part 211 covers: current Good Manufacturing Practices for finished pharmaceuticals. This regulation sets the baseline quality system for how finished drug products are produced, controlled, and distributed, aiming to ensure consistent quality, safety, and efficacy. Subparts A through K lay out the full framework—general provisions, organization and personnel, buildings and facilities, equipment, control of components and closures, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and handling of returned drug products. This is focused on manufacturing quality, not safety reporting or laboratory testing standards. Pharmacovigilance and adverse event reporting pertain to post-market safety surveillance, while Good Laboratory Practices govern nonclinical lab studies, not the manufacturing of finished drugs.

The statement tested here hinges on recognizing what 21 CFR Part 211 covers: current Good Manufacturing Practices for finished pharmaceuticals. This regulation sets the baseline quality system for how finished drug products are produced, controlled, and distributed, aiming to ensure consistent quality, safety, and efficacy. Subparts A through K lay out the full framework—general provisions, organization and personnel, buildings and facilities, equipment, control of components and closures, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and handling of returned drug products. This is focused on manufacturing quality, not safety reporting or laboratory testing standards. Pharmacovigilance and adverse event reporting pertain to post-market safety surveillance, while Good Laboratory Practices govern nonclinical lab studies, not the manufacturing of finished drugs.